•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Marti Is Highly Risky, Financially And Operationally
Marti Technologies, Inc. (MRT) Q1 2026 Earnings Call Transcript
Marti Delivers 156% Revenue Growth, 72% Gross Profit Margin in First Quarter 2026, with Significant Improvement in Profitability; Reaffirms Guidance
Marti Technologies, Inc. to Report 2026 First Quarter Results on May 21, 2026
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Morguard Real Estate Investment Trust (MRT.UN:CA) Q1 2026 Earnings Call Transcript
Marti Announces a New Share Repurchase Program
Marti Technologies, Inc. Files Annual Report on Form 20-F for Fiscal Year 2025
Marti: A Potential Early-Stage Opportunity Has Emerged
Marti Technologies, Inc. (MRT) Q4 2025 Earnings Call Transcript
Marti Revenue Increases 110%, Delivers 61% Gross Profit Margin for Full-Year 2025
Marti Technologies, Inc. to Report 2025 Fiscal Year Results on April 13, 2026
Marti's Ride-Hailing Service Reaches 3.80 Million Riders and 490 Thousand Registered Drivers, Exceeding March 31, 2026 Targets
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Marti Launches Shareholder Loyalty Program
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Morguard Real Estate Investment Trust (MRT.UN:CA) Q4 2025 Earnings Call Transcript
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects